Anzeige
Mehr »
Login
Dienstag, 27.07.2021 Börsentäglich über 12.000 News von 669 internationalen Medien
Ausbruch nach Auszeichnung - Startet jetzt die NASDAQ-Rallye?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
119 Leser
Artikel bewerten:
(0)

Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference

EAST BRUNSWICK, N.J., Jan.5, 2012 /PRNewswire/ --Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Noble Financial Capital Markets Eighth Annual Equity Conference on Tuesday, January 17, 2012 at 10:00 AM Eastern Time. The conference will be held at the Seminole Hard Rock Hotel in Hollywood, Florida.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com. Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUTSAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc.is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses fromDuke University("Duke") andMountain View Pharmaceuticals, Inc.("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP andDukehave been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website atwww.savient.com.

SVNT - G

Contact:

Mary Coleman

Carney Noensie

Savient Pharmaceuticals, Inc.

Burns McClellan

information@savient.com

cnoensie@burnsmc.com

(732) 418-9300

(212) 213-0006

SOURCE Savient Pharmaceuticals, Inc.

Kostenloser Wertpapierhandel auf Smartbroker.de
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.